High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma

References

• Armitage J O. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• DeVita V T, Jr., Hubbard S M. Hodgkin's disease. N Engl J Med 1993; 328: 560–565
   PubMed Web of Science ®Google Scholar
• Linch D C, Winfield D, Goldstone A H, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Gianni A M, Siena S, Bregni M, et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991; 2: 645–653
   PubMed Web of Science ®Google Scholar
• Gianni A M, Siena S, Bregni M, et al. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease–a 6-year update. Ann Oncol 1993; 4: 889–891
   PubMed Web of Science ®Google Scholar
• Gianni A M, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297
   PubMed Web of Science ®Google Scholar
• Abali H, Koc Y, Oyan B, Tekin F, Tekuzman G, Kansu E. IIVP salvage regimen induces high response rates in patients with relapsed HD or NHL prior to autologous HSCT [abstract]. Blood 2002; 100: 4714a
   Google Scholar
• Cheson B D, Horning S J, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Kaplan E J, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972; 135: 185–206
   Web of Science ®Google Scholar
• Longo D L, Duffey P L, Young R C, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210–218
   PubMed Web of Science ®Google Scholar
• Crump M, Smith A M, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704–711
   PubMed Web of Science ®Google Scholar
• Rapoport A P, Rowe J M, Kouides P A, et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351–2361
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467–475
   PubMed Web of Science ®Google Scholar
• Vose J M, Zhang M J, Rowlings P A, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Nimer S D, Zelenetz A D, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616–623
   PubMed Web of Science ®Google Scholar
• Shipp M A, Abeloff M D, Antman K H, et al. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol 1999; 10: 13–19
   PubMed Web of Science ®Google Scholar
• Prince H M, Imrie K, Crump M, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 1996; 92: 880–889
   PubMed Web of Science ®Google Scholar
• Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003; 97: 2748–2759
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116–123
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Conde Garcia E. Factors influencing the outcome of autologous stem cell transplant at first sensitive relapse in 247 adults with diffuse large-cell lymphoma [abstract]. Blood 2000; 96: 794a
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Hedrick E E, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399–2404
   PubMed Web of Science ®Google Scholar
• Johnston L J, Stockerl-Goldstein K E, Hu W W, et al. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 555–562
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Rambaldi A, Rossi A, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001; 114: 333–341
   PubMed Web of Science ®Google Scholar
• Kessinger A, Bierman P J, Vose J M, Armitage J O. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 77: 2322–2325
   PubMed Web of Science ®Google Scholar
• Majolino I, Pearce R, Taghipour G, Goldstone A H. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15: 509–517
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404
   PubMed Web of Science ®Google Scholar
• Yuen A R, Rosenberg S A, Hoppe R T, Halpern J D, Horning S J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814–822
   PubMed Web of Science ®Google Scholar
• Diehl V, Stein H, Hummel M, Zollinger R, Connors J M. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program) 2003; 225–247
   PubMedGoogle Scholar
• Shimoni A, Hardan I, Avigdor A, et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457–464
   PubMed Web of Science ®Google Scholar
• Brugger W, Hirsch J, Grunebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004; 15: 1691–1698
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92: 1933–1940
   PubMed Web of Science ®Google Scholar
• Darrington D L, Vose J M, Anderson J R, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527–2534
   PubMed Web of Science ®Google Scholar